Preparation of Particulate Polymeric Therapeutics for Medical Applications

Zhuang, Jia; Fang, Ronnie H.; Zhang, Liangfang

doi:10.1002/smtd.201700147

Cited by 32 publications

(26 citation statements)

References 230 publications

(245 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[36] In contrast to the saturation solubility of RAP in water (only ≈2.6 µg mL −1 ), [37] we were able to load 84.5 µg of RAP into 1 mL of PLGA aqueous solution (1 mg mL −1 ), thereby dramatically increasing its solubilization (more than 30 times greater than in water). We, therefore, generated RAP@PLGA by encapsulating the hydrophobic RAP into the hydrophobic "core" of PLGA using a nanoprecipitation method.…”

Section: Fabrication and Characterization Of Rbc/rap@plgamentioning

confidence: 86%

See 1 more Smart Citation

Biomimetic Nanotherapies: Red Blood Cell Based Core–Shell Structured Nanocomplexes for Atherosclerosis Management

et al. 2019

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of mortality worldwide. Atherosclerosis, one of the most common forms of the disease, is characterized by a gradual formation of atherosclerotic plaque, hardening, and narrowing of the arteries. Nanomaterials can serve as powerful delivery platforms for atherosclerosis treatment. However, their therapeutic efficacy is substantially limited in vivo due to nonspecific clearance by the mononuclear phagocytic system. In order to address this limitation, rapamycin (RAP)‐loaded poly(lactic‐ co ‐glycolic acid) (PLGA) nanoparticles are cloaked with the cell membrane of red blood cells (RBCs), creating superior nanocomplexes with a highly complex functionalized bio‐interface. The resulting biomimetic nanocomplexes exhibit a well‐defined “core–shell” structure with favorable hydrodynamic size and negative surface charge. More importantly, the biomimetic nature of the RBC interface results in less macrophage‐mediated phagocytosis in the blood and enhanced accumulation of nanoparticles in the established atherosclerotic plaques, thereby achieving targeted drug release. The biomimetic nanocomplexes significantly attenuate the progression of atherosclerosis. Additionally, the biomimetic nanotherapy approach also displays favorable safety properties. Overall, this study demonstrates the therapeutic advantages of biomimetic nanotherapy for atherosclerosis treatment, which holds considerable promise as a new generation of drug delivery system for safe and efficient management of atherosclerosis.

show abstract

Section: Fabrication and Characterization Of Rbc/rap@plgamentioning

confidence: 86%

“…[36] Briefly, RAP (1 mg) and PLGA (10 mg) were dissolved into dimethyl sulfoxide (DMSO) (1 mL). [36] Briefly, RAP (1 mg) and PLGA (10 mg) were dissolved into dimethyl sulfoxide (DMSO) (1 mL).…”

Section: Methodsmentioning

confidence: 99%

Biomimetic Nanotherapies: Red Blood Cell Based Core–Shell Structured Nanocomplexes for Atherosclerosis Management

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Prolonged release for 5–6 days is achieved by simply loading the drug molecules in MeHA matrix. Even slower release can be achieved by conjugating the drug molecules with HA molecules to form nanoparticulate conjugates 46 . Two weeks of sustained release can be attained when HA-IgG conjugates are loaded in MeHA matrix (Supplementary Fig.…”

Section: Discussionmentioning

confidence: 99%

Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery

et al. 2018

View full text Add to dashboard Cite

Eye diseases and injuries impose a significant clinical problem worldwide. Safe and effective ocular drug delivery is, however, challenging due to the presence of ocular barriers. Here we report a strategy using an eye patch equipped with an array of detachable microneedles. These microneedles can penetrate the ocular surface tissue, and serve as implanted micro-reservoirs for controlled drug delivery. The biphasic drug release kinetics enabled by the double-layered micro-reservoirs largely enhances therapeutic efficacy. Using corneal neovascularization as the disease model, we show that delivery of an anti-angiogenic monoclonal antibody (DC101) by such eye patch produces ~90% reduction of neovascular area. Furthermore, quick release of an anti-inflammatory compound (diclofenac) followed by a sustained release of DC101 provides synergistic therapeutic outcome. The eye patch application is easy and minimally invasive to ensure good patient compliance. Such intraocular drug delivery strategy promises effective home-based treatment of many eye diseases.

show abstract

“…A typical nanoprecipitation method usually requires that the hydrophobic payloads and polymer are dissolved together in a water-miscible organic solvent, with the lipid dissolved in an aqueous phase. 91,92 Compared with the aforementioned ESE method, the biggest difference is the need to heat the lipid-containing aqueous solution beyond its gel-to-liquid transition temperature in order to achieve a homogeneously dispersed liquid crystalline phase. 41 Aer dropwise addition of the polymer into the lipid under continuous stirring, the lipids will self-assemble onto the polymer nanoparticles via hydrophobic interactions.…”

Section: Nanoprecipitation Methodmentioning

confidence: 99%